Our objective is to convert innovative concepts into therapeutic products by utilizing our proficiency in bioconjugation technologies and medicinal chemistry. We foresee a future in which bioconjugates, including antibody-drug and antibody-oligonucleotide conjugates, exceed current standards, providing pioneering solutions for diseases currently considered untreatable. Bethel Bioconjugates aspires to become a global leader in advancing bioconjugation science, establishing it as a reproducible, scalable engineering discipline.
Bethel Biocon fast-tracks bioconjugate concepts into clinical candidates by offering top-tier non-GMP R&D services to innovators, biotech startups, and pharmaceutical companies. We specialize in bridging discovery and development, transforming targeted-therapy ideas into scalable, analytically defined conjugates for IND-enabling studies. Our mission is to provide scientific excellence and practical solutions that help clients advance their pipelines while enhancing their internal capabilities.
Bioconjugation technologies and platforms
Custom linker–payload design informed by medicinal chemistry and SAR
DOE-driven process development and scale-down modeling
Advanced purification and analytical characterization
R&D-grade material generation with manufacturability assessment
Supporting Innovation Across the Bioconjugation Ecosystem
Our team is led by PhD-level experts with decades of experience in medicinal chemistry and bioconjugation. We drive agile, non-GMP R&D with scientific precision, focusing on quality and rapid turnaround.
Find Out More